Do analysts recommend SVRA or NLTX?

Savara currently has a consensus price target of $10.25, suggesting a potential upside of 115.34%. Given Savara's stronger consensus rating and higher possible upside, research analysts plainly believe Savara is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Savara 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, SVRA or NLTX?

Savara is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is SVRA or NLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Neoleukin Therapeutics N/A -37.22% -30.91%

Do analysts prefer KURA or NLTX?

Kura Oncology presently has a consensus price target of $25.35, indicating a potential upside of 163.82%. Given Kura Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Kura Oncology is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.77 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer NLTX or MLTX?

MoonLake Immunotherapeutics has a consensus target price of $28.50, indicating a potential upside of 181.07%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MoonLake Immunotherapeutics 3 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has higher valuation & earnings, NLTX or MLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A

Is NLTX or MLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% MoonLake Immunotherapeutics N/A -82.53% -58.17%

Do analysts rate ANL or NLTX?

Adlai Nortye presently has a consensus target price of $29.50, indicating a potential upside of 171.14%. Given Adlai Nortye's stronger consensus rating and higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, ANL or NLTX?

Adlai Nortye has higher revenue and earnings than Neoleukin Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 140.13 -$35.53M N/A N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is ANL or NLTX more profitable?

Adlai Nortye's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Neoleukin Therapeutics N/A -37.22% -30.91%

Do analysts rate ALMS or NLTX?

Alumis currently has a consensus price target of $33.27, indicating a potential upside of 449.05%. Given Alumis' stronger consensus rating and higher probable upside, equities analysts clearly believe Alumis is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.86 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Neoleukin Therapeutics (NLTX) Competitors

$21.56 -2.88 (-11.78%)

As of 10/13/2026

Compare

NLTX vs. SVRA, KURA, MLTX, ANL, and ALMS

Should you buy Neoleukin Therapeutics stock or one of its competitors? Neoleukin Therapeutics's main competitors and comparable companies include Savara (SVRA), Kura Oncology (KURA), MoonLake Immunotherapeutics (MLTX), Adlai Nortye (ANL), and Alumis (ALMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neoleukin Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Savara is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

In the previous week, Savara had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Savara and 0 mentions for Neoleukin Therapeutics. Savara's average media sentiment score of 0.32 beat Neoleukin Therapeutics' score of 0.00 indicating that Savara is being referred to more favorably in the media.

Company	Overall Sentiment
Savara	Neutral
Neoleukin Therapeutics	Neutral

Savara currently has a consensus price target of $10.25, suggesting a potential upside of 115.34%. Given Savara's stronger consensus rating and higher possible upside, research analysts plainly believe Savara is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Savara has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

87.9% of Savara shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Neoleukin Therapeutics' return on equity of -37.22% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Savara beats Neoleukin Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Neoleukin Therapeutics has lower revenue, but higher earnings than Kura Oncology. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	11.07	-$278.67M	-$3.37	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Kura Oncology presently has a consensus price target of $25.35, indicating a potential upside of 163.82%. Given Kura Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Kura Oncology is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Neoleukin Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Neoleukin Therapeutics' return on equity of -37.22% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Kura Oncology has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Kura Oncology had 9 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 9 mentions for Kura Oncology and 0 mentions for Neoleukin Therapeutics. Kura Oncology's average media sentiment score of 0.33 beat Neoleukin Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Kura Oncology	Neutral
Neoleukin Therapeutics	Neutral

Summary

Kura Oncology beats Neoleukin Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to MoonLake Immunotherapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Neoleukin Therapeutics' return on equity of -37.22% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 0 mentions for Neoleukin Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.10 beat Neoleukin Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
MoonLake Immunotherapeutics	Positive

MoonLake Immunotherapeutics has a consensus target price of $28.50, indicating a potential upside of 181.07%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MoonLake Immunotherapeutics	3 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.43

Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Summary

MoonLake Immunotherapeutics beats Neoleukin Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Adlai Nortye presently has a consensus target price of $29.50, indicating a potential upside of 171.14%. Given Adlai Nortye's stronger consensus rating and higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Adlai Nortye's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

In the previous week, Adlai Nortye had 4 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for Adlai Nortye and 0 mentions for Neoleukin Therapeutics. Adlai Nortye's average media sentiment score of 0.87 beat Neoleukin Therapeutics' score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Overall Sentiment
Adlai Nortye	Positive
Neoleukin Therapeutics	Neutral

Adlai Nortye has higher revenue and earnings than Neoleukin Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	140.13	-$35.53M	N/A	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Adlai Nortye has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Adlai Nortye beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Neoleukin Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Neoleukin Therapeutics' return on equity of -37.22% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 33.7% of Alumis shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neoleukin Therapeutics has lower revenue, but higher earnings than Alumis. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	32.61	-$243.32M	-$3.86	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

In the previous week, Alumis had 11 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 11 mentions for Alumis and 0 mentions for Neoleukin Therapeutics. Alumis' average media sentiment score of 0.57 beat Neoleukin Therapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the media.

Company	Overall Sentiment
Alumis	Positive
Neoleukin Therapeutics	Neutral

Alumis currently has a consensus price target of $33.27, indicating a potential upside of 449.05%. Given Alumis' stronger consensus rating and higher probable upside, equities analysts clearly believe Alumis is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Alumis has a beta of -0.38, meaning that its stock price is 138% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Summary

Alumis beats Neoleukin Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NLTX vs. The Competition

Export

Metric	Neoleukin Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$202.62M	$3.84B	$7.18B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.60%
P/E Ratio	-6.93	9.86	213.76	19.47
Price / Sales	N/A	1,170.93	573.62	81.29
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	1.95	16.02	10.29	5.92
Net Income	-$57.56M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-16.66%	-5.88%	-3.54%	-3.85%
1 Month Performance	-38.77%	-12.92%	-7.80%	-6.37%
1 Year Performance	-35.06%	2.99%	0.77%	-6.01%

Neoleukin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NLTX Neoleukin Therapeutics	N/A	$21.56 -11.8%	N/A	-31.8%	$202.62M	N/A	N/A	90	High Trading Volume
SVRA Savara	2.0911 of 5 stars	$4.88 +4.9%	$10.25 +110.0%	+40.8%	$955.39M	N/A	N/A	70
KURA Kura Oncology	3.5179 of 5 stars	$10.67 +1.3%	$25.69 +140.7%	-0.1%	$936.76M	$67.48M	N/A	260	Analyst Forecast
MLTX MoonLake Immunotherapeutics	2.86 of 5 stars	$10.77 -1.6%	$28.50 +164.6%	+0.0%	$931.92M	N/A	N/A	130
ANL Adlai Nortye	2.371 of 5 stars	$14.05 -2.8%	$29.50 +110.0%	+547.6%	$931.19M	$5M	N/A	109	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. SVRA, KURA, MLTX, ANL, and ALMS

How does Neoleukin Therapeutics compare to Savara?

Summary

How does Neoleukin Therapeutics compare to Kura Oncology?

Summary

How does Neoleukin Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Neoleukin Therapeutics compare to Adlai Nortye?

Summary

How does Neoleukin Therapeutics compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. SVRA, KURA, MLTX, ANL, and ALMS

How does Neoleukin Therapeutics compare to Savara?

Which has stronger valuation and earnings, SVRA or NLTX?

Does the media favor SVRA or NLTX?

Do analysts recommend SVRA or NLTX?

Which has more volatility and risk, SVRA or NLTX?

Do institutionals and insiders hold more shares of SVRA or NLTX?

Is SVRA or NLTX more profitable?

Summary

How does Neoleukin Therapeutics compare to Kura Oncology?

Which has stronger valuation and earnings, KURA or NLTX?

Do analysts prefer KURA or NLTX?

Is KURA or NLTX more profitable?

Which has more volatility & risk, KURA or NLTX?

Do insiders and institutionals believe in KURA or NLTX?

Does the media favor KURA or NLTX?

Summary

How does Neoleukin Therapeutics compare to MoonLake Immunotherapeutics?

Do institutionals & insiders have more ownership in NLTX or MLTX?

Is NLTX or MLTX more profitable?

Which has higher valuation & earnings, NLTX or MLTX?

Does the media prefer NLTX or MLTX?

Do analysts prefer NLTX or MLTX?

Which has more risk and volatility, NLTX or MLTX?

Summary

How does Neoleukin Therapeutics compare to Adlai Nortye?

Do analysts rate ANL or NLTX?

Is ANL or NLTX more profitable?

Does the media favor ANL or NLTX?

Which has higher earnings and valuation, ANL or NLTX?

Which has more risk & volatility, ANL or NLTX?

Do institutionals and insiders believe in ANL or NLTX?

Summary

How does Neoleukin Therapeutics compare to Alumis?

Is ALMS or NLTX more profitable?

Do insiders and institutionals believe in ALMS or NLTX?

Which has preferable valuation and earnings, ALMS or NLTX?

Does the media refer more to ALMS or NLTX?

Do analysts rate ALMS or NLTX?

Which has more volatility & risk, ALMS or NLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools